Application of artemisinin analogs in the preparation of drugs for reducing androgen levels and drugs for treating diseases associated with high androgen levels
By inhibiting CYP11A1 in ovarian membrane-stromal cells, artemisinin analogues reduce androgen levels, solving the problem of difficult to effectively treat high androgen-related diseases in the prior art, significantly improving the symptoms of PCOS patients and showing good results Security.
Patent Information
- Application Number
- CN202110938195.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-16
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-08-16
AI Technical Summary
The existing technology is difficult to effectively reduce androgen levels. The treatment of causative androgen-related diseases such as polycystic ovary syndrome (PCOS), and the role of commonly used drugs on lipid metabolism is controversial and the long-term effect is unknown.
Artemisinin analogues are used to reduce testosterone and androgen synthesis by inhibiting CYP11A1 protein levels in ovarian membrane-stromal cells, and to prepare drugs that reduce androgens for the prevention and treatment of hyperandrogenemia and polycystic ovarian synthesis. Contest.
Artemisinin analogues significantly reduce androgen levels, improve ovarian polycystic, abortion and abnormal glycolipid metabolism. Clinical application shows ideal safety and no intolerable side effects were found.
Smart Images

Figure CN115702893B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of artemisinin analogs in the preparation of androgen-reducing drugs and drugs for treating diseases associated with high androgen levels. Technical Background
[0002] Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine disorders in women of childbearing age and is the main cause of anovulatory infertility. In recent years, the incidence of PCOS in China has been rising year by year, and the incidence of PCOS in non-menopausal women aged 19-45 has increased from 5.6% in 2003 to 7.4%. According to the 2003 Rotterdam diagnostic criteria, the diagnosis of PCOS requires the presence of any two of the following three clinical manifestations: anovulation or oligoovulation, clinical manifestations of hyperandrogenemia and hyperandrogenism, and morphological polycystic ovaries (PCO). In addition to the above characteristic manifestations, studies have shown that 50% to 70% of PCOS patients have insulin resistance, and about 30% of obese PCOS patients have impaired glucose tolerance, and may develop type 2 diabetes in the long term. In addition, women with PCOS, especially those with obesity, may also suffer from cardiovascular diseases, hypertension, reproductive system tumors, and abnormal mental symptoms in the later stage, which seriously affect women's reproductive health and quality of life.
[0003] At present, the specific etiology and pathogenesis of PCOS are still unclear. In 2006, the American Androgen Society (AES) proposed that hyperandrogenemia is the main physiological and pathological basis of its onset. Hyperandrogenemia can cause follicular development disorders and abnormal ovulation, and is an endocrine disease with significant metabolic disorders. First, high levels of androgens cause female endocrine abnormalities, leading to disorders in the normal cyclical changes of sex hormones, affecting the normal development of follicles, the selection of dominant follicles and the appearance of hormone ovulation peaks, and then causing polycystic ovarian manifestations and anovulatory infertility; on the contrary, this abnormal ovarian structure directly affects the synthesis of normal sex hormones and their feedback regulation on the hypothalamus-pituitary-ovarian axis (HPO axis), resulting in a vicious cycle of elevated androgens. Furthermore, abnormal increases in androgens can cause a decrease in the production of sex hormone binding globulin (SHBG) in the liver. Androgens bound to SHBG are usually inactive, so a decrease in SHBG can lead to an increase in the level of the active form of androgen (free testosterone), prompting the formation of hyperandrogenic signs in PCOS patients, mainly manifested as acne, hirsutism, and hair loss. Therefore, the regulation of androgen levels in women is of great significance for maintaining endocrine homeostasis.
[0004] Androgens in women include androstenedione, testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and dihydrotestosterone, which are mainly secreted by the ovaries and adrenal glands, and ovarian theca cells are the main source of female blood androgens. The secretion of basal androgens and the secretion capacity of ovarian androgens in PCOS patients during the reproductive period are significantly enhanced, and 90% of patients have significantly increased serum androgen levels. It is currently believed that the dysfunction of the hypothalamus-pituitary-ovarian axis (HPO axis), abnormal follicular development and atresia, inflammation and the regulation of multiple factors such as the insulin growth factor system, the renin-angiotensin system (RAS), adiponectin, leptin, and growth hormone are all involved in the pathogenesis of abnormal androgen elevation. The follicles of PCOS patients often mature prematurely and then atresia. The aromatase activity of atretic follicles decreases, resulting in an increase in testosterone and dehydrotestosterone. In addition, follicular atresia leads to apoptosis of granulosa cells and is replaced by theca cells and fibroblasts, which continue to synthesize large amounts of testosterone and androstenedione under the action of high levels of luteinizing hormone (LH). Androgen is a steroid hormone. Cholesterol is catalyzed by cytochrome P450 side chain cleavage enzyme (CYP11A1), cytochrome P450c17α hydroxylase (CYP17A1) and 3-β-hydroxysteroid dehydrogenase (HSD3β2) in ovarian theca cells to form androgen precursors such as progesterone, and finally produce androgen. The key enzymes of androgen synthesis CYP11A1 and CYP17A1 in PCOS patients are hyperfunctional, and androgen synthesis increases; while 3β-hydroxysteroid dehydrogenase, 17-steroid reductase and aromatase in the androgen metabolic pathway are missing, resulting in androgen accumulation and increased serum androgen levels. In addition, more and more studies in recent years have shown that hyperandrogenemia is highly correlated with insulin resistance. On the one hand, high concentrations of insulin can promote the secretion of LH by the pituitary gland and directly act on ovarian theca cells, leading to increased androgen synthesis; on the other hand, it can also inhibit the synthesis of SHBG in the liver, leading to increased levels of free androgens and increased androgen utilization. Therefore, hyperandrogenism is not only a gynecological endocrine-related disease, but also belongs to the category of metabolic syndrome.
[0005] In recent years, a large number of clinical trials have shown that reducing the serum androgen level of patients can significantly alleviate the symptoms of polycystic ovary, anovulation, abnormal glucose and lipid metabolism, and hyperandrogenism in PCOS. Clinically, hypoglycemic drugs are often used in combination with diet and exercise to regulate the body's metabolic state, and their effects on reproductive outcomes are positive and affirmative. The effects of commonly used anti-androgen drugs such as Diane-35 on lipid metabolism are still controversial. Although metformin, a drug for the treatment of insulin resistance, and lipid-lowering drugs such as statins have the effect of improving lipid metabolism disorders, their effects on lowering androgen levels and improving ovulation are not ideal, and whether they are beneficial for long-term treatment still needs to be further verified through rigorous experimental design and large-sample studies.
[0006] Artemisinin drugs include artemether, artesunate and dihydroartemisinin, arteether, SM905, Artemiside, artemisone and artemether maleate (SM934) and other structures. Artemisinin drugs are one of the first-line drugs for the clinical treatment of malaria. They can efficiently and quickly kill intraerythrocytic malarial parasites. They are clinically used to treat chloroquine-resistant malignant malaria and severe malaria. They have the advantages of rapid efficacy, good short-term efficacy, and low toxicity and side effects. They are widely used in clinical practice. Recent studies have shown that artemisinin analogs also have significant therapeutic effects in tumor treatment and immune regulation, and have shown excellent potential in the treatment of liver cancer, prostate cancer and autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis).
[0007] Currently, the potential application of artemisinin analogs in androgen-related diseases has not been discovered. Summary of the invention
[0008] Technical problem to be solved by the invention
[0009] The purpose of the present invention is to provide a new use of artemisinin analogs in pharmaceutical manufacturing, and specifically to use of artemisinin analogs in the preparation of drugs for reducing androgen and treating diseases associated with high androgen levels.
[0010] Technical means to solve technical problems
[0011] To achieve the above-mentioned object, the first aspect of the present invention provides the use of an artemisinin analogue represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing androgen.
[0012]
[0013] Wherein, R is selected from the group consisting of hydroxyl, methoxy, ethoxy, succinic acid monoester, 2-aminoethoxy, 2R-3-tert-butylamino-2-hydroxypropoxy, thiomorpholinyl and 1,1-dioxide thiomorpholinyl.
[0014] Another aspect of the present invention provides use of an artemisinin analogue represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating diseases associated with high androgen levels.
[0015] In the present invention, the disease associated with high androgen levels is hyperandrogenemia.
[0016] In the present invention, the disease associated with high androgen levels is polycystic ovary syndrome.
[0017] In the present invention, the polycystic ovary syndrome is estrous cycle arrest.
[0018] In the present invention, the polycystic ovary syndrome is polycystic ovary.
[0019] In the present invention, the artemisinin analogue reduces androgen by inhibiting the synthesis of androgen in ovarian theca-stromal cells.
[0020] In the present invention, the androgen is testosterone, and androgen precursors progesterone and 17α-hydroxyprogesterone.
[0021] In the present invention, the artemisinin analogues inhibit androgen synthesis by inhibiting the CYP11A1 protein level in ovarian theca-stromal cells.
[0022] In the present invention, the dosage form of the drug is not particularly limited, and may be, for example, an oral preparation and / or an injection. When it is an oral preparation, the content of the artemisinin analogue is not less than 0.5 g, and when it is an injection, the content of the artemisinin analogue is not less than 0.2 g.
[0023] In the present invention, the artemisinin analogue represented by formula (I) is:
[0024] Artemisinin analogs R Dihydroartemisinin Hydroxyl Artemether Methoxy Artemether Ethoxy Artesunate Succinic acid monoester group (succinate group) Artemetheramide 2-Aminoethoxy SM905 2R-3-tert-Butylamino-2-hydroxypropoxy artemiside Thiomorpholinyl Artemisinin 1,1-Thiomorpholinyl dioxide
[0025] In the present invention, the artemisinin analogue is preferably a compound artemether represented by formula (A) or a compound artemetheramide represented by formula (B).
[0026]
[0027] The pharmaceutically acceptable salts mentioned in the present invention include salts formed between artemisinin analogs and organic or inorganic acids.
[0028] Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like.
[0029] Organic acids include, but are not limited to, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, maleic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, aspartic acid, and the like.
[0030] The dosage form of the drug mentioned in the present invention can be an existing commonly used preparation, including but not limited to oral preparations, injections, suppositories, or coatings, etc.
[0031] The drug of the present invention includes but is not limited to liposome preparations, nanoparticle preparations, solid dispersions, self-emulsifiers, transdermal administration agents, β-cyclodextrin inclusion compounds or phospholipid complexes.
[0032] The administration routes of the drug of the present invention include, but are not limited to, intravenous, transdermal, intradermal, subcutaneous, intramuscular, intraperitoneal, oral, rectal, intranasal or a combination thereof.
[0033] Beneficial technical effects
[0034] The present invention has confirmed through in vivo and in vitro experiments that artemisinin analogs have the effect of reducing androgens in female animals, and by affecting ovarian testosterone synthesis, they have the effect of regulating hormone levels, improving ovulation and restoring estrous cycles, and improving symptoms related to polycystic ovary syndrome. Clinical application practice shows that no intolerable side effects have been found. Therefore, overall, as a clinical drug, artemisinin analogs have ideal safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 The results show the effect of preventive intraperitoneal injection of artemether 30 mg / kg on the reduction of serum testosterone levels in PCOS mice. **p<0.01;
[0036] Figure 2 The results showed that the preventive intraperitoneal injection of artemether 30 mg / kg improved the estrous cycle of PCOS mice.
[0037] Figure 3 The results showed that the preventive intraperitoneal injection of artemether 30 mg / kg alleviated the polycystic changes in the ovaries of PCOS mice.
[0038] Figure 4 It was shown that prophylactic intraperitoneal injection of artemether 30 mg / kg did not produce hepatotoxicity in PCOS mice;
[0039] Figure 5 It is shown that therapeutic intraperitoneal injection of artemether reduces serum testosterone levels in PCOS mice, *p<0.05;
[0040] Figure 6 It was shown that therapeutic intraperitoneal injection of artemether did not affect serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in PCOS mice;
[0041] Figure 7 The results showed that intraperitoneal injection of artemether improved the estrous cycle of PCOS mice.
[0042] Figure 8 The results showed that intraperitoneal injection of artemether alleviated polycystic changes in the ovaries of PCOS mice.
[0043] Fig. 9 It is shown that therapeutic oral administration of artemether reduces serum testosterone levels in PCOS mice, **p<0.01;
[0044] Fig.10 It was shown that therapeutic oral administration of artemether did not affect serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in PCOS mice;
[0045] Fig.11 The therapeutic oral administration of artemether improves the estrous cycle of PCOS mice.
[0046] Fig.12 The effects of therapeutic oral administration of artemether on polycystic ovarian changes and corpus luteum in PCOS mice are shown;
[0047] Fig.13 It shows that different doses of artemether inhibit the levels of testosterone, progesterone and 17α-hydroxyprogesterone produced by mouse ovarian theca-interstitial cells;
[0048] Fig.14 The effects of different doses of artemether on the levels of CYP11A1, HSD3B2, CYP17A1, and β-actin proteins in the theca-stromal cells of the mice ovaries are shown;
[0049] Fig.15 The effects of different doses of artemether on the expression levels of Cyp11a1, Hsd3b2, and Cyp17a1 genes in the theca-stromal cells of the ovary of mice are shown;
[0050] Fig.16 It shows that different doses of SM934 inhibit the levels of testosterone, progesterone and 17α-hydroxyprogesterone produced by mouse ovarian theca-interstitial cells;
[0051] Fig.17 The graph shows the effects of different doses of SM934 on the gene expression levels of CYP11A1, HSD3B2, CYP17A1, and β-actin in mouse ovarian theca-stromal cells.
[0052] Fig.18 The figure shows the effects of different doses of artesunate on the gene expression levels of CYP11A1, HSD3B2, CYP17A1, and β-actin in the theca-stromal cells of the mouse ovary. DETAILED DESCRIPTION
[0053] The present invention will be further described in detail below in conjunction with specific embodiments and drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The protection scope of the present invention shall be subject to the claims.
[0054] Experimental methods in the examples of this specification where specific conditions are not specified are generally carried out according to conventional conditions in the art or according to the conditions recommended by the manufacturer's instructions.
[0055] Unless otherwise specified, in the present invention, "%" means mass % and "percentage" means mass percentage.
[0056] Example 1: Artemether preventively inhibits the increase of serum androgen levels in PCOS mouse models and improves polycystic ovary syndrome Changes and estrous cycle
[0057] 1.1 Materials
[0058] 1.1.1 Animals: 5-week-old C57BL / 6J mice, SPF grade, female, provided by Nanjing Model Organisms Co., Ltd. Animal license number: SCXK (Su) 2018-0008.
[0059] The mice were kept in separate cages, and were allowed to drink water and eat freely. The humidity in the laboratory was maintained at 40%-70%, and the temperature was controlled at 18℃-22℃. The light and dark hours were alternating for 12 hours, and the environment was kept quiet. Mouse feed, bedding, and all experimental conditions were provided by the Key Laboratory of Metabolic Molecular Medicine of the Ministry of Education, Fudan University. After 3 days of routine adaptive feeding of mice, modeling, grouping, and experiments were started.
[0060] 1.1.2 Artemether (Chengdu Pufeide Biotechnology Co., Ltd.)
[0061] 1.1.3 Dehydroepiandrosterone DHEA (produced by Shanghai Puzhen Biotechnology Co., Ltd., CAS No.: 53-43-0)
[0062] 1.1.4 Coconut oil (Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No.: 8001-31-8)
[0063] 1.2 Equipment
[0064] 1.2.1 Microscope Olympus IX711
[0065] 1.2.2 Eppendorf Centrifuge 5427R
[0066] 1.2.3 Clean bench (Suzhou Antai Air Technology Co., Ltd.)
[0067] 1.2.4 Centrifuge Eppendorf
[0068] 1.2.5 Hormone level measuring machine (Beckman connector unicel Dxi800)
[0069] 1.2.6 Paraffin embedding machine THERMO Shandon Finesse325 (Thermo Shandon, USA)
[0070] 1.2.7 Dehydrator Excelsior (new dehydrator) (Thermo Shandon, USA)
[0071] 1.2.8 Paraffin slicer Histoxentre (Thermo Shandon, USA)
[0072] 1.3 Equipment
[0073] 1.3.1 Surgical instruments: elbow ophthalmic forceps, straight ophthalmic forceps, elbow ophthalmic scissors, straight ophthalmic scissors
[0074] 1.3.2 Tin Foil
[0075] 1.3.3 Syringe (1ml, 10ml, Insulin Syringe)
[0076] 1.3.4 Slides and coverslips (Sinopharm)
[0077] 1.4 Solution
[0078] 1.4.1 4% polymethanol fixative
[0079] 1.4.2 PBS buffer (pH 7.4: potassium dihydrogen phosphate (KH2PO4): 0.27 g, sodium dihydrogen phosphate (Na2HPO4):
[0080] 1.42g, sodium chloride (NaCl): 8g, potassium chloride (KCl) 0.2g, add about 800mL of deionized water and stir thoroughly to dissolve, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally adjust the volume to 1L)
[0081] 1.4.3 CMC solution (1.5% carboxymethyl cellulose)
[0082] 1.4.4 DHEA preparation method:
[0083]
[0084] 1.5 Methods
[0085] 1.5.1 Establishment of PCOS model in mice and preventive artemether treatment
[0086] Dehydroepiandrosterone and artemether were dissolved in a small amount of 95% ethanol, and then dissolved in coconut oil (the solvent was a composite solvent, and the preliminary experiments showed that the composite solvent was safe for mice). Female mice aged 5 to 6 weeks were randomly divided into groups. The modeling group mice were subcutaneously injected with dehydroepiandrosterone solution (DHEA 60mg / kg) on the back of the neck, and the control group mice were subcutaneously injected with the same dose of composite solvent. At the same time as the modeling, the composite solvent and artemether (30mg / kg) were injected intraperitoneally, once a day, for 60 days. The mice were divided into four groups: 1) composite solvent + composite solvent (control group); 2) composite solvent + artemether; 3) DHEA + composite solvent; 4) DHEA + artemether.
[0087] 1.5.2 Mouse estrous cycle detection:
[0088] Determine the estrus cycle by observing the vaginal epithelial cell smear of mice: After 60 days of treatment in 1.5.1 above, take the mice for continuous vaginal cell smears for 10 days to observe the continuous keratinization of vaginal epithelial cells. The simple process is as follows: In the clean bench, lift the mouse tail, use a pipette to draw physiological saline and repeatedly perfuse it into the vaginal opening, and evenly apply it on the slide. After the slide is dry, stain it with Wright's staining solution, let it air dry naturally, and observe the epithelial cell morphology under a microscope.
[0089] 1.5.3 Determination of biochemical indicators of sex hormones in mouse serum: 60 days after the treatment in 1.5.1 above, 300-400 μL of blood was collected from the orbital venous plexus, left to stand at room temperature for 2 h, centrifuged at 1000 g for 20 min, and about 100 μL of the upper phase serum was collected. The serum total testosterone level was measured using a Beckman automatic biochemical analyzer.
[0090] 1.5.4 Pathological observation of mouse ovarian tissue: 60 days after the treatment in 1.5.1 above, the experimental mice were killed by cervical dislocation after anesthesia, and the bilateral ovaries were fixed in 4% paraformaldehyde solution for 24 hours and observed under a microscope after H&E staining.
[0091] 1.5.5 Evaluation of the effect of artemether on liver injury indicators in mice: 60 days after the treatment in 1.5.1 above, 300-400 μL of blood was collected from the orbital venous plexus, left to stand at room temperature for 2 h, centrifuged at 1000 g for 20 min, and about 100 μL of upper phase serum was collected. The serum ALT and AST levels were detected using a Beckman automatic biochemical analyzer.
[0092] 1.6 Results
[0093] 1.6.1 Artemether preventively inhibits DHEA-induced androgen elevation in PCOS mice
[0094] like Figure 1 As shown, the androgen level of mice in the DHEA+complex solvent group was significantly increased compared with that in the complex solvent+complex solvent control group, indicating the occurrence of hyperandrogenemia in PCOS mice; while the androgen level of mice in the DHEA+artemether group was significantly decreased, indicating that artemether preventively reduced the androgen level of PCOS mice.
[0095] 1.6.2 Artemether prevents estrous cycle arrest in PCOS model mice
[0096] The existence of estrous cycle can reflect the ovulation of mice. The estrous cycle of PCOS mice generally stagnates, indicating that their ovulation is abnormal. Figure 2 As shown, vaginal smear test of estrus cycle found that the control group of compound solvent + compound solvent ( Figure 2 a) and combined solvent + artemether mice ( Figure 2The vaginal epithelial cell smears of the DHEA+complex solvent group ( Figure 2 c) The vaginal smears of mice showed obvious continuous keratinization or cycle arrest of epithelial cells, while the DHEA+artemether (ATM) group ( Figure 2 d) Mice showed obvious activity cycles. Although the cycle time was prolonged, the regularity was significantly restored.
[0097] 1.6.3 Artemether prevents polycystic changes in the ovaries of PCOS model mice
[0098] Ovarian morphological changes are often important observation indicators for establishing PCOS models. Figure 3 As shown in the figure, the morphological observation of ovarian tissue pathological sections showed that the DHEA+compound solvent group ( Figure 3 c) Cystic dilated follicles and multicystic pathological changes were observed in the mouse ovaries. Figure 3 d) Ovarian morphology improves in polycystic ovaries.
[0099] 1.6.4 Artemether treatment does not cause liver damage in mice
[0100] Toxicity is one of the important indicators for evaluating drugs. We collected serum from mice treated with artemether and tested ALT (alanine aminotransferase) and AST (aspartate aminotransferase). Figure 4 As shown, compared with the control group, artemether did not affect the ALT and AST levels of mice, indicating that intraperitoneal injection of artemether did not cause liver damage to mice.
[0101] Example 2: Intraperitoneal injection of artemether therapeutically inhibits the increase in serum androgen levels in PCOS mouse models and improves Polycystic ovarian changes and estrous cycle
[0102] 2.1 Materials
[0103] 2.1.1 Animals: 5-week-old C57BL / 6J mice, SPF grade, female, provided by Nanjing Model Organisms Co., Ltd. Animal license number: SCXK (Su) 2018-0008
[0104] The mice were kept in separate cages, with free access to water and food. The humidity in the laboratory was maintained at 40%-70%, and the temperature was controlled at 18℃-22℃. The light and dark hours were alternating for 12 hours, and the environment was kept quiet. Mouse feed, bedding, and all experimental conditions were provided by the Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University. After 3 days of routine adaptive feeding of mice, modeling, grouping, and experiments were started.
[0105] 2.1.2 Artemether (Chengdu Pufeide Biotechnology Co., Ltd.)
[0106] 2.1.3 Dehydroepiandrosterone (produced by Shanghai Puzhen Biotechnology Co., Ltd., CAS No.: 53-43-0)
[0107] 2.1.4 Coconut oil (Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No.: 8001-31-8)
[0108] 2.1.5 Anhydrous ethanol (Shanghai Heying Chemical Co., Ltd., CAS No.: 64-17-5)
[0109] 2.2 Equipment
[0110] 2.2.1 Microscope Olympus IX711
[0111] 2.2.2 Eppendorf Centrifuge 5427R
[0112] 2.2.3 Clean bench (Suzhou Antai Air Technology Co., Ltd.)
[0113] 2.2.4 Centrifuge Eppendorf
[0114] 2.2.5 Hormone level measuring machine (Beckman connector unicel Dxi800)
[0115] 2.2.6 Paraffin embedding machine THERMO Shandon Finesse325 (Thermo Shandon, USA)
[0116] 2.2.7 Dehydrator Excelsior (new dehydrator) (Thermo Shandon, USA)
[0117] 2.2.8 Paraffin slicer Histoxentre (Thermo Shandon, USA)
[0118] 2.3 Equipment
[0119] 2.3.1 Surgical instruments: elbow ophthalmic forceps, straight ophthalmic forceps, elbow ophthalmic scissors, straight ophthalmic scissors
[0120] 2.3.2 Tin Foil
[0121] 2.3.3 Syringe (1ml, 10ml, Insulin Syringe)
[0122] 2.3.4 Slides and coverslips (Sinopharm)
[0123] 2.4 Solution
[0124] 2.4.1 4% polymethanol fixative
[0125] 2.4.2 PBS buffer (pH 7.4: potassium dihydrogen phosphate (KH2PO4): 0.27g, disodium hydrogen phosphate (Na2HPO4): 1.42g, sodium chloride (NaCl): 8g, potassium chloride (KCl) 0.2g, add about 800mL of deionized water and stir thoroughly to dissolve, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally adjust the volume to 1L)
[0126] 2.5 Methods
[0127] 2.5.1 Establishment of PCOS model in mice and intraperitoneal injection of therapeutic artemether
[0128] Dehydroepiandrosterone and artemether were dissolved in a small amount of 95% ethanol, and then dissolved in coconut oil (the solvent was a composite solvent, and preliminary experiments have shown that the composite solvent is safe for mice). Female mice aged 5 to 6 weeks were randomly divided into groups, and dehydroepiandrosterone solution (60 mg / kg) was injected subcutaneously at the back of the neck of the mice, once a day, for 60 days to establish a PCOS model. After the model was successfully established, the PCOS mice were randomly divided into three groups: 1) PCOS + composite solvent; 2) PCOS + artemether (30 mg / kg); 3) PCOS + artemether (60 mg / kg); artemether was administered by intraperitoneal injection, once a day.
[0129] 2.5.2 Mouse estrous cycle detection: same as 1.5.2
[0130] 2.5.3 Determination of biochemical indicators of sex hormones in mouse serum: Same as 1.5.3
[0131] 2.5.4 Pathological observation of mouse ovarian tissue: same as 1.5.4
[0132] 2.6 Results
[0133] 2.6.1 Intraperitoneal injection of artemether to treat high androgen levels in PCOS mice
[0134] DHEA injection can establish a PCOS model, and the androgen level of mice is significantly increased. Figure 5 As shown in Figure 2, intraperitoneal injection of artemether can significantly reduce the androgen level of PCOS mice, and the effect of artemether (60 mg / kg) in reducing androgen is better than that of artemether (30 mg / kg). Figure 6 As shown, artemether treatment did not change the levels of gonadotropins including luteinizing hormone LH and follicle stimulating hormone FSH in mice.
[0135] 2.6.2 Treatment of estrous arrest in PCOS mice by intraperitoneal injection of artemether
[0136] like Figure 7As shown, vaginal smear test of estrous cycle revealed that the estrous cycle of the PCOS model established by DHEA injection was arrested, and intraperitoneal injection of artemether was able to significantly restore the regular estrous cycle.
[0137] 2.6.3 Polycystic ovarian changes in PCOS mice treated with intraperitoneal injection of artemether
[0138] like Figure 8 As shown, morphological examination of the ovaries revealed polycystic changes in PCOS mice, and intraperitoneal injection of artemether could improve the polycystic changes in the ovaries.
[0139] Example 3: Oral administration of artemether therapeutically inhibited the increase in serum androgen levels in PCOS mouse models and improved ovarian function Polycystic changes and estrous cycle
[0140] 3.1 Materials
[0141] 3.1.1 Animals: Animals: 5-week-old C57BL / 6J mice, SPF grade, female, provided by Nanjing Model Organisms Co., Ltd. Animal license number: SCXK (Su) 2018-0008
[0142] The mice were kept in separate cages, with free access to water and food. The humidity in the laboratory was maintained at 40%-70%, and the temperature was controlled at 18℃-22℃. The light and dark hours were alternating for 12 hours, and the environment was kept quiet. Mouse feed, bedding, and all experimental conditions were provided by the Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University. After 3 days of routine adaptive feeding of mice, modeling, grouping, and experiments were started.
[0143] 3.1.2 Artemether (Chengdu Pufeide Biotechnology Co., Ltd.)
[0144] 3.1.3 Dehydroepiandrosterone (produced by Shanghai Puzhen Biotechnology Co., Ltd., CAS No.: 53-43-0)
[0145] 3.1.4 Coconut oil (Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No.: 8001-31-8)
[0146] 3.2 Equipment
[0147] 3.2.1 Microscope Olympus IX711
[0148] 3.2.2 Eppendorf Centrifuge 5427R
[0149] 3.2.3 Clean bench (Suzhou Antai Air Technology Co., Ltd.)
[0150] 3.2.4 Centrifuge Eppendorf
[0151] 3.2.5 Hormone level measuring machine (Beckman connector unicel Dxi800)
[0152] 3.2.6 Paraffin embedding machine THERMO Shandon Finesse325 (Thermo Shandon, USA)
[0153] 3.2.7 Dehydrator Excelsior (New dehydrator) (Thermo Shandon, USA)
[0154] 3.2.8 Paraffin slicer Histoxentre (Thermo Shandon, USA)
[0155] 3.3 Equipment
[0156] 3.3.1 Surgical instruments: straight forceps, elbow hemostatic forceps, surgical scissors, blood collection needle, procoagulant negative pressure blood collection tube
[0157] 3.3.2 Tin Foil
[0158] 3.3.3 Syringe (1ml, 10ml, Insulin Syringe)
[0159] 3.3.4 Slides and coverslips (Sinopharm)
[0160] 3.4 Solution
[0161] 3.4.1 4% polymethanol fixative
[0162] 3.4.2 PBS buffer (pH 7.4: potassium dihydrogen phosphate (KH2PO4): 0.27 g, disodium hydrogen phosphate (Na2HPO4): 1.42 g, sodium chloride (NaCl): 8 g, potassium chloride (KCl) 0.2 g, add about 800 mL of deionized water and stir thoroughly to dissolve, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally adjust the volume to 1 L)
[0163] 3.4.3 CMC solution (1.5% carboxymethyl cellulose)
[0164] 3.5 Methods
[0165] 3.5.1 Establishment of PCOS model in mice and therapeutic oral administration of artemether
[0166] Dehydroepiandrosterone was dissolved in a small amount of 95% ethanol, and then dissolved in coconut oil (the solvent was a composite solvent, and preliminary experiments have shown that the composite solvent is safe for mice). Artemisinin was resuspended using CMC solution. Female mice aged 5 to 6 weeks were randomly divided into groups, and dehydroepiandrosterone solution (DHEA 60 mg / kg) was subcutaneously injected into the back of the neck of the mice, once a day, for 60 days to establish a PCOS model. After the model was successfully established, the PCOS mice were randomly divided into two groups: 1) PCOS + CMC solvent; 2) PCOS + artemisinin (100 mg / kg). Artemisinin was administered by oral gavage once a day.
[0167] 3.5.2 Mouse estrous cycle detection: same as 1.5.2
[0168] 3.5.3 Determination of biochemical indicators of sex hormones in mouse serum: Same as 1.5.3
[0169] 3.5.4 Pathological observation of mouse ovarian tissue: same as 1.5.4
[0170] 3.6 Results
[0171] 3.6.1 Oral administration of artemether reduces androgen levels in PCOS mice
[0172] Oral administration of artemether can significantly reduce the androgen level of DHEA-induced PCOS model (such as Fig. 9 ), but does not change the levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (as shown in Fig.10 shown).
[0173] 3.6.2 Oral administration of artemether to treat estrous arrest in PCOS mice
[0174] like Fig.11 As shown, vaginal smear test of estrous cycle found that the estrous cycle of PCOS model established by DHEA injection was arrested, and oral administration of artemether could significantly restore the regular estrous cycle.
[0175] 3.6.3 Intraperitoneal injection of artemether to treat polycystic ovarian changes in PCOS mice
[0176] like Fig.12 As shown, morphological examination of the ovaries revealed polycystic changes in PCOS mice. Oral administration of artemether could improve polycystic changes in the ovaries and increase the number of corpora lutea.
[0177] Example 4: Artemether reduces the level of androgen synthesis in mouse theca-lesional cells
[0178] 4.1 Materials
[0179] 4.1.1 Animals: 5-week-old C57BL / 6JN mice, SPF grade, female, provided by Nanjing Model Organisms Co., Ltd. Animal license number: SCXK (Su) 2018-0008.
[0180] The mice were kept in separate cages and given free access to water and food. The humidity in the laboratory was maintained at 40%-70% and the temperature was controlled at 18℃-22℃. The light and dark periods were alternating for 12 hours, and the environment was kept quiet. Mouse feed, bedding and all experimental conditions were provided by the Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University.
[0181] 4.1.2 McCoy's 5A medium (Gibco)
[0182] 4.1.3 Lebovitz's L-15 medium (Gibco)
[0183] 4.1.4 Fetal bovine serum (Gibco)
[0184] 4.1.6 Penicillin and Streptomycin
[0185] 4.1.7 Artemether (Chengdu Pufeide Biotechnology Co., Ltd.)
[0186] 4.1.8 Trizol (Life Technology)
[0187] 4.1.9 Reverse transcription kit (ThermoScientific)
[0188] 4.1.10 Power SYBR Green Master Mix(ThermoScientific)
[0189] 4.2 Equipment
[0190] 4.2.1 Constant temperature sterile incubator Thermo Scientific Forma Series II Water Jacket
[0191] 4.2.2 Real-time quantitative PCR instrument Applied Biotech 7500 real time PCR System
[0192] 4.2.3 Microscope Olympus IX711
[0193] 4.2.4 Eppendorf Centrifuge 5427R
[0194] 4.2.5 Nucleic Acid Quantification Instrument Colibri
[0195] 4.2.6 Centrifuge Eppendorf
[0196] 4.2.7 Hormone level measuring machine (Beckman connector unicel Dxi800)
[0197] 4.3 Equipment
[0198] 4.3.1 Surgical instruments: elbow ophthalmic forceps, straight ophthalmic forceps, elbow ophthalmic scissors, straight ophthalmic scissors
[0199] 4.3.2 Tin Foil
[0200] 4.3.3 Filter head (0.22 μm)
[0201] 4.3.4 24-well plate (BD falcon)
[0202] 4.3.5 Syringe (1ml, 10ml, Insulin Syringe)
[0203] 4.4 Solution
[0204] 4.4.1 Culture medium
[0205] Lebovitz's L-15 washing medium
[0206] Lebovitz's L-15 500ml Fetal bovine serum 10% Biotin 8mg / ml penicillin 100U / ml Streptomycin 0.1mg / mL
[0207] McCoy's 5A maintenance medium
[0208] McCoy's 5A 500ml Fetal bovine serum 10% Biotin 8mg / ml penicillin 100U / ml Streptomycin 0.1mg / ml
[0209] Ovarian digestive fluid
[0210] McCoy's 5A At least 100 μl / ovary Fetal bovine serum 10% Collagenase type IV 4mg / ml
[0211] 4.4.2 Artemether stock solution was dissolved in DMSO and the stock concentration was 10 mM.
[0212] 4.4.3 PBS buffer (pH 7.4: potassium dihydrogen phosphate (KH2PO4): 0.27 g, disodium hydrogen phosphate (Na2HPO4): 1.42 g, sodium chloride (NaCl): 8 g, potassium chloride (KCl) 0.2 g, add about 800 mL of deionized water and stir thoroughly to dissolve, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally adjust the volume to 1 L)
[0213] 4.5 Methods
[0214] 4.5.1 Isolation and culture of mouse ovarian theca-stromal cells
[0215] (1) 21-25 day old C57BL / 6 female mice were killed by cervical dislocation. The ovaries on both sides were aseptically removed from the midline incision of the lower back and washed twice in washing solution. The fat tissue and capsule around the ovaries were separated under a stereomicroscope, and the clean and intact ovaries were washed twice in washing solution.
[0216] (2) Under a stereomicroscope, mechanically puncture the ovaries with a 25-gauge 1 ml syringe needle and a blood collection needle to release as many granulosa cells as possible from the follicles.
[0217] (3) Repeatedly wash the fragmented tissue in the washing solution, collect the remaining fragmented tissue, add a small amount of digestive solution and cut it into pieces with ophthalmic scissors, and then add an appropriate amount of digestive solution as needed (ensuring 100 μl / ovary).
[0218] (4) Digest in a water bath at 37°C for 60-90 min, using 100 μL of digestion solution per ovary. During the digestion process, shake the tissue several times every 10 min to ensure that the tissue is fully digested.
[0219] (5) Filter the digested cell suspension with a filter and centrifuge (1000g, 5min). Discard the supernatant and wash once with McCoy's 5a medium and centrifuge again (1000g, 5min). Add an appropriate amount of McCoy's 5A medium (500uL for one ovary).
[0220] (6) The cells finally obtained were resuspended in McCoy's 5A medium and counted (10 μL of cells and 90 μL of culture solution were added to a measuring cup for counting. The value after counting x 10 was the desired cell concentration). The number of cells in each well was about 1×10^5. The cells were placed in a 37°C, 95% 02-5% CO2 incubator for 24 h. The cells adhered and the culture medium was replaced. The culture medium was replaced every other day thereafter.
[0221] 4.5.2 Artemether treatment of mouse ovarian theca-stromal cells
[0222] When the above-isolated mouse ovarian theca-stromal cells proliferated to about 60-70%, the medium was changed and different concentrations of artemether were added to divide into four groups: 1) artemether 0 μM; 2) artemether 1 μM; 3) artemether 5 μM; 4) artemether 10 μM. After artemether treatment for 48 hours, the cell supernatant and cells were collected.
[0223] 4.5.3 Detection of androgen levels in the supernatant of ovarian theca-stromal cell culture
[0224] Ovarian theca-stromal cells were treated with artemether according to the method in 4.5.3, the supernatant was collected, and serum total testosterone was detected using Beckman automatic biochemical analyzer.
[0225] 4.5.4 Extraction of total cell RNA and reverse transcription into cDNA
[0226] Ovarian mesenchymal cells were treated with artemether according to the method in 4.5.3. After collecting the cells and washing them with PBS, the cells were fully lysed with 1ml Trizol, and after thorough mixing, 200μl of chloroform was added, and after vigorous shaking, the cells were allowed to stand at room temperature for 15min, and centrifuged at 4℃, and the centrifugation conditions were 12000g for 10min. At this time, due to the chromatography effect, the lysate was divided into three layers. The upper aqueous phase solution was carefully transferred to a new centrifuge tube, 500μl of isopropanol was added, and the cells were allowed to stand at room temperature for 10 minutes after gentle mixing. The cells were centrifuged at 4℃, 12000g for 10min, and the supernatant was discarded. A milky white translucent precipitate was visible at the bottom of the tube. The precipitate was washed with 75% ethanol, and centrifuged at 4℃7500g for 5min. The supernatant was discarded, and the precipitate was dried at room temperature. The precipitate was dissolved in 60μl of DEPC water, and quantified with Colibri Tepertec and stored at -80℃.
[0227] Take 1 μg RNA for reverse transcription to synthesize the corresponding cDNA, PrimeScript reverse transcription kit. The synthesis system is as follows:
[0228] 5x PrimeScript Reverse Transcriptase Mix 2μl RNA template 0.5 μg DEPC water Up to 10 μl
[0229] The synthesis conditions are as follows:
[0230] 37℃ 15min 85℃ 10s 4℃ extend
[0231] The synthesized cDNA was stored in a -20°C refrigerator.
[0232] 4.5.5 qPCR
[0233] Reaction system:
[0234] CYBR Green Master Mix 5μl Upstream primer 0.5μl Downstream primer 0.5μl RNA template 1μl <![CDATA[ddH2O]]> 3μl
[0235] Each duplicate well has 10μ system, and each reaction has three duplicate wells. The master tube is configured and then dispensed into the duplicate wells. The qPCR reaction is carried out in an ABI7500 fluorescence quantitative PCR instrument. The reaction conditions are:
[0236]
[0237] Reaction conditions:
[0238] The forward primer sequence for amplifying 18SrRNA is GTAACCCGTTGAACCCCATT; the reverse primer sequence is CCATCCAATCGGTAGTAGCG.
[0239] The forward sequence for amplifying CYP11A1 was AGGTCCTTCAATGAGATCCCTT; the reverse primer was TCCCTGTAAATGGGGCCATAC.
[0240] The forward sequence for amplifying CYP17A1 was GCCCAAGTCAAAGACACCTAAT; the reverse primer was GTACCCAGGCGAAGAGAATAGA.
[0241] The forward sequence for amplifying HSD3β2 was GGTTTTTGGGGCAGAGGATCA; the reverse primer was GGTACTGGGTGTCAAGAATGTCT.
[0242] The relative amount of mRNA was calculated according to the ΔΔCT method, using 18SrRNA as the internal reference, and then the control mRNA level was set to 1. Each treatment group was compared with the control group to obtain the relative amount.
[0243] 4.5.6 Extraction of total cell protein
[0244] Treat ovarian mesenchymal cells with artemether according to the method in 4.5.3. Collect cells and use lysis buffer to fully lyse the cells. Transfer the lysate to a 1.5 ml centrifuge tube, heat at 100 ° C for 10 min, centrifuge at 13000g for 10 min at 4 ° C, transfer the clarified lysate in the middle layer to a new centrifuge tube, take 2.5 μl of lysate for quantification using the BCA method, incubate at 37 ° C for 30 min, cool to room temperature, and measure the absorbance at 562 nm. Draw a standard curve and calculate the concentration of the sample to be tested.
[0245] 4.5.7 Western blot
[0246] Take 30 μg of theca-interstitial cell protein and load it onto a 10% polyacrylamide gel for electrophoresis. Use 80V for electrophoresis of the base gel and 100V for electrophoresis of the separation gel until the target band is dispersed. Transfer the membrane to a PVDF membrane in an ice bath at 300 mA for 100 min. After the transfer, block it in 5% skim milk prepared with TBST (TBS buffer + 0.5% Tween) for 1 hr. Incubate with specific antibodies at 4°C overnight. The next day, wash the PVDF membrane with TBST, room temperature, 10 min, wash three times, co-incubate with the corresponding secondary antibody, room temperature for 1 hr, wash three times with TBST, use the same antibody under the same conditions, co-incubate with the chemiluminescent reagent, room temperature for 1 min, expose with ImageQuant LAS4000 Mini automatic chemiluminescence instrument, and record the results.
[0247] Antibody catalog numbers and antibody dilution ratios are shown in the table below:
[0248]
[0249] 4.5.8 Data Analysis
[0250] The data differences were analyzed by Student's t-test or one-way ANOVA method, and statistical differences were considered when p < 0.05.
[0251] 4.6 Results
[0252] 4.6.1 Artemether reduces androgen secretion levels in primary cultured mouse thermionic-interstitial cells
[0253] The above animal experiments have found that artemether can reduce the androgen level in mice, but does not affect the levels of gonadotropin-releasing hormone and gonadotropin. Therefore, we speculate that artemether may directly regulate androgen synthesis in ovarian tissue. In ovarian theca-stromal cells, the secretion of androgens by the theca-stromal cells after artemether treatment decreased in a dose-dependent manner with the increase of artemether treatment concentration. In addition, Fig.13 As shown in the results, artemether treatment can dose-dependently downregulate the levels of testosterone and the androgen upstream hormones progesterone and 17-α-hydroxyprogesterone. This means that artemisinin derivatives downregulate the levels of precursor hormones in the androgen synthesis pathway, thereby reducing androgen levels.
[0254] 4.6.2 Artemether inhibits CYP11A1 levels in mouse thermionic-interstitial cells
[0255] Androgens are steroid hormones produced from cholesterol under the catalysis of CYP11A1, CYP17A1 and HSD3β2. We treated mouse theca-stromal cells with artemether, such as Fig.14 As shown in Figure 2, Western blot analysis revealed that artemether dose-dependently downregulated the protein level of CYP11A1, but did not affect the protein levels of CYP17A1 and HSD3B2. Fig.15 As shown, qPCR detection found that artemether did not affect the mRNA levels of CYP11A1, CYP17A1 and Hsd3b2.
[0256] Example 5, maleic acid Artemetheramide Reduced androgen synthesis in mouse thermionic-interstitial cells
[0257] 5.1-5.5
[0258] The same method as 4.1-4.5 in Example 4 was followed except that artemether was replaced by artemether maleate. Example 5 was carried out.
[0259] 5.6 Results
[0260] 5.6.1 Artemether maleate reduces androgen secretion levels in primary cultured mouse thermionic-interstitial cells
[0261] In the ovarian theca-stromal cells, the secretion of androgens by the theca-stromal cells after treatment with artemether maleate decreased in a dose-dependent manner with the increase in the concentration of artemether maleate treatment. In addition, as shown in Figure 16, artemether maleate treatment can dose-dependently downregulate the levels of androgen upstream hormones progesterone, 17-α-hydroxyprogesterone and testosterone. This means that artemisinin derivatives downregulate the levels of precursor hormones in the androgen synthesis pathway, thereby reducing androgen levels.
[0262] 5.6.2 Artemetheramide maleate inhibits CYP11A1 levels in mouse thermionic-interstitial cells
[0263] Androgens are steroid hormones produced from cholesterol under the catalysis of CYP11A1, CYP17A1 and HSD3β2. We treated mouse mesenchymal cells with artemetheramide maleate. Fig.17 As shown, Western blot analysis revealed that artemether maleate dose-dependently downregulated the protein level of CYP11A1, but had no effect on the protein levels of CYP17A1 and HSD3B2.
[0264] Example 6 Artesunate reduces CYP11A1 levels in mouse mesenchymal cells
[0265] The same method as in Example 4 was used to Artesunate reduces CYP11A1 levels in the theca-lesional cells of mice Experiment The results showed that artesunate could dose-dependently downregulate CYP11A1 levels ( Fig.18 ).
Claims
1. Use of an artemisinin analogue represented by formula (I) or a pharmaceutically acceptable salt thereof as the sole active ingredient in the preparation of a medicament for preventing and / or treating polycystic ovary syndrome, in, R is selected from the group consisting of hydroxy, methoxy, ethoxy, succinic acid monoester and 2-aminoethoxy.
2. The use according to claim 1, wherein the artemisinin analogue prevents and / or treats polycystic ovary syndrome by reducing androgen levels.
3. The method according to claim 1, wherein the polycystic ovary syndrome is estrous cycle arrest.
4. The use according to claim 1, wherein the polycystic ovary syndrome is polycystic ovary.
5. The use according to claim 2, characterized in that The artemisinin analogs reduce androgens by inhibiting the synthesis of androgens in ovarian theca-stromal cells.
6. The use according to claim 2, wherein the androgen is testosterone, progesterone and 17α-hydroxyprogesterone.
7. The use according to claim 5, characterized in that The artemisinin analogues inhibit androgen synthesis by suppressing the CYP11A1 protein level in ovarian theca-stromal cells.
8. The use according to claim 1, wherein the drug is an oral preparation and / or an injection, and when it is an oral preparation, the content of the artemisinin analogue is not less than 0.5g, and when it is an injection, the content of the artemisinin analogue is not less than 0.2g.
